Clinical trials: Active Population
Crohn's Disease
A Pilot Study of FFP104 in Subjects With Crohn's Disease
This study will be conducted to evaluate the safety, tolerability and efficacy of intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with moderate to severely active Crohn's Disease
- Trial name
- NCT02465944
- Testing
- FFP104
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 24 people
- Sponsor
- Fast Forward Pharmaceuticals
Hypertension
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure.
- Trial name
- NCT00635232
- Testing
- irbesartan, PS433540
- Where
- 40 sites in United States
- Volunteers
- 261 people
- Sponsor
- Ligand Pharmaceuticals
Facial Rosacea
Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea
To evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Zydus Worldwide DMCC) and Soolantra® (ivermectin) cream, 1% (Galderma Laboratories, L.P.) in the treatment of moderate to severe facial papulopustular…
- Trial name
- NCT04106726
- Testing
- Soolantra® Ivermectin cream 1%, Ivermectin cream 1%
- Where
- 11 sites in United States
- Volunteers
- 525 people
- Sponsor
- Zydus Worldwide DMCC
Alzheimer's Disease
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal…
- Trial name
- NCT01399125
- Testing
- Rivastigmine Patch, Rivastigmine Capsules
- Where
- 16 sites in China
- Volunteers
- 501 people
- Sponsor
- Novartis Pharmaceuticals
Arthralgia, Bunion
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.
The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of 2 different dose levels of tapentadol (CG5503) compared with oxycodone and with placebo in subjects who have…
- Conditions
- Arthralgia, Bunion, Hallux Valgus, Pain
- Trial name
- NCT00613938
- Testing
- Tapentadol (CG5503), oxycodone
- Where
- 7 sites in United States
- Volunteers
- 901 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Crohn's Disease
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
- Trial name
- NCT00291668
- Testing
- Certolizumab Pegol
- Where
- 22 sites in Japan
- Volunteers
- 94 people
- Sponsor
- UCB Pharma
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00650338
- Testing
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Santen Inc.
Psoriasis, Plaque Psoriasis
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPACT (NCT02346240)
- Testing
- Certolizumab Pegol, Etanercept
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 559 people
- Sponsor
- UCB Biopharma S.P.R.L.
Diabetes Mellitus, Type 2
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
The primary objective of this study is to compare the effect of albiglutide and exenatide on gastric myoelectrical activity (GMA), gastric emptying (GE) and nausea (as measured by visual analogue scale [VAS]) in subjects with…
- Trial name
- NCT02793154
- Testing
- Exenatide, Albiglutide
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
This study is to evaluate the efficacy and safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes. The primary objective is to demonstrate equivalence of QLG1091 and Rybelsus.
- Trial name
- NCT07487103
- Testing
- QLG1091, Rybelsus
- Volunteers
- 478 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Adenocarcinoma of the Prostate
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to participants followed on active surveillance…
- Trial name
- ProVent (NCT03686683)
- Testing
- sipuleucel-T
- Where
- 56 sites in United States
- Volunteers
- 532 people
- Sponsor
- Dendreon
Systemic Lupus Erythematosus
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
- Trial name
- NCT03742037
- Testing
- Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg
- Where
- 148 sites in United States, Bulgaria and 22 more
- Volunteers
- 427 people
- Sponsor
- Viatris Innovation GmbH
Gastroesophageal Reflux
Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms
The study is designed to assess the effect and safety of oral administration of VECAM 40/300 administered at bedtime compared to Esomeprazole 20 mg administered 30-60 minutes before dinner, for control of nighttime and daytime HB…
- Trial name
- NCT01059383
- Testing
- VECAM 40/300, Esomeprazole 20 mg
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Vecta Ltd.
Pulmonary Disease, Chronic Obstructive
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
The primary objectives of the study are to explore the effect of treatment with orally inhaled tiotropium + olodaterol fixed dose combination with and without exercise training, and tiotropium comparing to placebo, on top of…
- Trial name
- NCT02085161
- Testing
- tiotropium+olodaterol, tiotropium +olodaterol, tiotropium
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- Boehringer Ingelheim
Congestive Heart Failure
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
To confirm the non-inferiority of OPC-61815 16-mg injection to tolvaptan 15-mg tablet using as the primary endpoint the change in body weight following 5-day intravenous administration of OPC-61815 16-mg injection or 5-day oral…
- Trial name
- NCT03772041
- Testing
- OPC-61815, Tolvaptan Tab 15 MG
- Where
- Japan
- Volunteers
- 294 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder
The purpose of this randomized, double blind, double dummy, multicenter study was to evaluate the efficacy of risperidone long-acting injectable (LAI) monotherapy in comparison with placebo in the prevention of a mood episode in…
- Trial name
- NCT00391222
- Testing
- Olanzapine, Risperidone Long Acting Injectable (LAI)
- Where
- 63 sites in China, Colombia and 13 more
- Volunteers
- 585 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Osteoarthritis of the Knee
Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee
The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747 versus placebo in relieving pain in participants with osteoarthritis of the knee.
- Trial name
- NCT00979953
- Testing
- ADL5859, ADL5747, Oxycodone CR
- Where
- 11 sites in United States
- Volunteers
- 408 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prostatic Hyperplasia
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate.
- Trial name
- NCT00457457
- Testing
- Tamsulosin, UK-369,003
- Where
- 46 sites in Australia, Belgium and 13 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Schizophrenia
A Study of Paliperidone Palmitate 6-Month Formulation
The main purpose of this study is to assess the long-term safety and tolerability of paliperidone 6-month PP6M (Dose 1 or Dose 2 [milligram] mg eq.) and to provide access to PP6M in participants with schizophrenia completing the…
- Trial name
- NCT04072575
- Testing
- PP6M injection Dose 1, PP6M injection Dose 2
- Where
- 30 sites in Argentina, Hong Kong and 4 more
- Volunteers
- 178 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Rheumatoid
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)
This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis
- Trial name
- NCT00256919
- Testing
- GW856553
- Where
- 17 sites in Bulgaria, Germany and 3 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.